{"ticker": {"uuid": "4d1b09e9-8114-4477-b472-fc0b09a640f2", "symbol": "MLYS", "name": "Mineralys Therapeutics, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Mineralys Therapeutics (MLYS) affiliate plans 7,438-share stock sale after options exercise", "summary": "An affiliate of Mineralys Therapeutics (MLYS) has filed a Form 144 notice for the potential sale of 7,438 shares of common stock. This sale, valued at $199,884.80, is scheduled for July 21, 2026, following the exercise of employee stock options via a broker-assisted cashless exer", "url": "https://www.stocktitan.net/sec-filings/MLYS/144-mineralys-therapeutics-inc-sec-filing-5744e9a702e7.html", "source_name": "Stock Titan", "published_at": "2026-07-21T20:40:14", "published_display": "21 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares By Investing.com", "summary": "Mineralys Therapeutics CMO David Rodman sold 416 shares for $11,036 while simultaneously acquiring the same number of shares by exercising stock options for $6,423 under a pre-arranged trading plan. Post-transaction, Rodman holds 51,384 shares and 3,334 stock options. The company", "url": "https://za.investing.com/news/stock-market-news/mineralys-therapeutics-cmo-david-rodman-disposes-of-11036-in-shares-93CH-4377548", "source_name": "Investing.com South Africa", "published_at": "2026-07-21T15:40:14", "published_display": "21 Jul 2026 15:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Mineralys Therapeutics Inc For: 21 July", "summary": "This article states that a Form 4 was filed for Mineralys Therapeutics Inc. on July 21st, implying a report of changes in beneficial ownership of the company's securities. The content is primarily a placeholder for this regulatory filing, with minimal actual news text and surroun", "url": "https://ca.investing.com/news/stock-market-news/form-4-mineralys-therapeutics-inc-for-21-july-93CH-4743146", "source_name": "Investing.com Canada", "published_at": "2026-07-21T09:40:18", "published_display": "21 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares", "summary": "Mineralys Therapeutics' Chief Medical Officer, David Rodman, recently sold 416 shares for $11,036 and simultaneously acquired 416 shares through stock option exercise for $6,423. These transactions were under a Rule 10b5-1 trading plan. The company's stock has seen a 96% return o", "url": "https://www.investing.com/news/insider-trading-news/mineralys-therapeutics-cmo-david-rodman-disposes-of-11036-in-shares-93CH-4802288", "source_name": "Investing.com", "published_at": "2026-07-21T09:40:18", "published_display": "21 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Mineralys Therapeutics For: 17 July By Investing.com", "summary": "This article from Investing.com is a brief notice about a Form 144 filing for Mineralys Therapeutics (MLYS) on July 17. Form 144 is an SEC filing that indicates an intent to sell restricted securities. The article provides minimal detail beyond this announcement.", "url": "https://ca.investing.com/news/stock-market-news/form-144-mineralys-therapeutics-for-17-july-93CH-4740463", "source_name": "Investing.com Canada", "published_at": "2026-07-17T21:11:19", "published_display": "17 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) insider schedules 416-share sale after option exercise", "summary": "Mineralys Therapeutics (MLYS) insider David Rodman has scheduled a sale of 416 common shares on July 17, 2026, following the exercise of employee stock options via a cashless exercise through Merrill Lynch. This notice also details several prior share sales by Rodman between Apri", "url": "https://www.stocktitan.net/sec-filings/MLYS/144-mineralys-therapeutics-inc-sec-filing-2c5d30ba343d.html", "source_name": "Stock Titan", "published_at": "2026-07-17T20:09:46", "published_display": "17 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date", "summary": "", "url": "https://finance.yahoo.com/m/f28c48e6-c98a-3312-a19f-022e3dbbc272/a-mineralys-insider-banked-a.html", "source_name": "Motley Fool", "published_at": "2026-07-16T21:05:05+00:00", "published_display": "16 Jul 2026 21:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What to Know About This Mineralys Insider Sale Before a December FDA Date", "summary": "", "url": "https://finance.yahoo.com/m/e0203402-60fc-310d-8601-a25fe170a689/what-to-know-about-this.html", "source_name": "Motley Fool", "published_at": "2026-07-16T20:57:38+00:00", "published_display": "16 Jul 2026 20:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary", "summary": "Mineralys Therapeutics (MLYS) provided updates at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026. Key announcements included the late 2025 NDA submission for lorundrostat with a PDUFA date of December 6, 2026, and preparations for its launch. The company also ", "url": "https://quartr.com/events/mineralys-therapeutics-inc-mlys-goldman-sachs-47th-annual-global-healthcare-conference-2026_FkT72ETU", "source_name": "Quartr", "published_at": "2026-07-16T21:09:46", "published_display": "16 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mineralys Therapeutics (MLYS) Q3 2025 earnings summary", "summary": "Mineralys Therapeutics (MLYS) reported its Q3 2025 earnings, highlighting plans for NDA submission of lorundrostat by early 2026 following positive FDA feedback. The company's cash position of $593.6 million is expected to fund operations into 2028, with significant public equity", "url": "https://quartr.com/events/mineralys-therapeutics-inc-mlys-q3-2025_FkT7DPvK", "source_name": "Quartr", "published_at": "2026-07-16T10:40:56", "published_display": "16 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Mineralys Therapeutics Inc For: 15 July By Investing.com", "summary": "This article reports on a Form 4 filing for Mineralys Therapeutics Inc. for July 15. The brief piece includes the company's stock symbol (MLYS) and a minor percentage change. The content primarily lists market data for various indices, commodities, bonds, and shares.", "url": "https://ng.investing.com/news/stock-market-news/form-4-mineralys-therapeutics-inc-for-15-july-93CH-2601912", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T02:39:36", "published_display": "16 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: CEO Jon Congleton Sells 10,700 Shares of Mineralys Therapeutics Inc (MLYS)", "summary": "Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton sold 10,700 shares on July 13, 2026, reducing his total holdings to 603,621 shares. This transaction is part of a trend of more insider selling than buying at the company over the past year. Shares were trading at $27.24 at the ", "url": "https://www.gurufocus.com/news/8961504/insider-sell-ceo-jon-congleton-sells-10700-shares-of-mineralys-therapeutics-inc-mlys", "source_name": "GuruFocus", "published_at": "2026-07-16T02:39:36", "published_display": "16 Jul 2026 02:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics CEO Jon Congleton sells $291,441 in stock", "summary": "Mineralys Therapeutics CEO Jon Congleton sold 10,700 shares of company stock, valued at $291,441, on July 13, 2026, as part of a pre-planned trading arrangement. Following this sale, Congleton still owns 603,621 shares. The company's stock has seen a significant return over the p", "url": "https://www.investing.com/news/insider-trading-news/mineralys-therapeutics-ceo-jon-congleton-sells-291441-in-stock-93CH-4794575", "source_name": "Investing.com", "published_at": "2026-07-16T01:39:36", "published_display": "16 Jul 2026 01:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys therapeutics CMO Rodman sells $556,671 in shares", "summary": "Mineralys Therapeutics' Chief Medical Officer, Rodman David Malcom, sold company shares totaling $556,671 across two transactions in July 2026, executed under a pre-arranged trading plan. Concurrently, he acquired shares worth $102,365 through stock option exercises. The company ", "url": "https://www.investing.com/news/insider-trading-news/mineralys-therapeutics-cmo-rodman-sells-556671-in-shares-93CH-4794576", "source_name": "Investing.com", "published_at": "2026-07-16T01:39:36", "published_display": "16 Jul 2026 01:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) CMO sells 20,407 shares and exercises options", "summary": "Mineralys Therapeutics (MLYS) Chief Medical Officer David Malcom Rodman sold 20,407 common shares and exercised options for 14,058 common shares on July 13 and 15, 2026. These transactions were executed under a Rule 10b5-1 trading plan adopted on October 6, 2025. Following these ", "url": "https://www.stocktitan.net/sec-filings/MLYS/form-4-mineralys-therapeutics-inc-insider-trading-activity-e2acc69c7499.html", "source_name": "Stock Titan", "published_at": "2026-07-16T00:40:56", "published_display": "16 Jul 2026 00:40", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) CEO logs 10,700-share sale under Rule 10b5-1 plan", "summary": "Mineralys Therapeutics CEO Jon Congleton sold 10,700 shares of common stock on July 13, 2026, at a weighted-average price of $27.2375 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in January 2025. Following the sale, Congleton dir", "url": "https://www.stocktitan.net/sec-filings/MLYS/form-4-mineralys-therapeutics-inc-insider-trading-activity-b51ef8b1e8b0.html", "source_name": "Stock Titan", "published_at": "2026-07-16T00:39:36", "published_display": "16 Jul 2026 00:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Planned 6,349-share stock sale by Mineralys Therapeutics (NASDAQ: MLYS)", "summary": "An insider at Mineralys Therapeutics (NASDAQ: MLYS), David Rodman, plans to sell 6,349 shares of common stock through Merrill Lynch on July 15, 2026, with an aggregate market value of approximately $168,954.55. These shares were acquired via an exercise of employee stock options ", "url": "https://www.stocktitan.net/sec-filings/MLYS/144-mineralys-therapeutics-inc-sec-filing-979899871b67.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:39:36", "published_display": "15 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Planned 14,058-share sale at Mineralys Therapeutics (NASDAQ: MLYS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQUG9lcm16bkFtRHUxUm95WFZ0UE1ONWZwRFFTTllLTWdZMmRjM1FOQ3AzZXVuU0tKX1NkVE5zckxEeDJ5N09UTm1LQUFBWkhRbHJKQmwwODdnWU0zZXdRNmJPeS1FcDgycTE1endYdTA1X0Q2T0tHUjN0dnhxWnlYMkdPekkyNm1hcTV1Q0hQVkJEcUx2YmFGRGxYSE1lLUJFVVRVZ0VNM1o?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T15:08:29+00:00", "published_display": "14 Jul 2026 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Mineralys Therapeutics For: 13 July By Investing.com", "summary": "The article announces the filing of Form 144 for Mineralys Therapeutics on July 13. It is a brief report from Investing.com, likely indicating an insider transaction or a notice of proposed sale of securities. The article provides minimal detail beyond the date and company name, ", "url": "https://ng.investing.com/news/stock-market-news/form-144-mineralys-therapeutics-for-13-july-93CH-2597728", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T02:10:38", "published_display": "14 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) insider plans 10,700-share Rule 144 stock sale", "summary": "Mineralys Therapeutics (MLYS) insider Jon Congleton plans to sell 10,700 shares of common stock under Rule 144, valued at $291,441.17. The sale, set for July 13, 2026, via Merrill Lynch on Nasdaq, follows the vesting of restricted stock units. Congleton has made previous sales to", "url": "https://www.stocktitan.net/sec-filings/MLYS/144-mineralys-therapeutics-inc-sec-filing-3f94c8183c17.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:10:39", "published_display": "13 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) insider details stock option exercise and sales", "summary": "An affiliate of Mineralys Therapeutics, Inc. (MLYS) has a planned sale of common stock via Merrill Lynch on NASDAQ, stemming from an employee stock option exercise on July 13, 2026. Insider David Rodman has made multiple open-market sales of the company's common stock in the past", "url": "https://www.stocktitan.net/sec-filings/MLYS/144-mineralys-therapeutics-inc-sec-filing-fc3ec0482ec2.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:10:38", "published_display": "13 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Mineralys Therapeutics, Inc. \u2013 NASDAQ:MLYS", "summary": "This article provides details about Mineralys Therapeutics, Inc. (NASDAQ: MLYS), including its stock information, market status, and links to financial data, news, and community discussions on TradingView. It also lists the various data providers for the information presented.", "url": "https://www.tradingview.com/symbols/NASDAQ-MLYS/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-13T08:39:36", "published_display": "13 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mineralys Therapeutics CMO Rodman sells $65,781 in stock", "summary": "Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, sold 2,171 shares of the company's stock for $65,781 on July 9, 2026, under a Rule 10b5-1 trading plan. This sale occurred after the stock delivered a 94% return over the past year, though shares are currently tr", "url": "https://www.investing.com/news/insider-trading-news/mineralys-therapeutics-cmo-rodman-sells-65781-in-stock-93CH-4787156", "source_name": "Investing.com", "published_at": "2026-07-11T07:10:46", "published_display": "11 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) CMO sells 2,171 shares after option exercise", "summary": "Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, exercised 2,171 stock options at $16.00 per share and subsequently sold the same number of common shares at $30.30 per share. This transaction was pre-planned under a Rule 10b5-1 trading plan adopted in October 2", "url": "https://www.stocktitan.net/sec-filings/MLYS/form-4-mineralys-therapeutics-inc-insider-trading-activity-81cf9763ea99.html", "source_name": "Stock Titan", "published_at": "2026-07-11T00:40:31", "published_display": "11 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Mineralys Therapeutics Inc For: 10 July By Investing.com", "summary": "This article reports on a Form 4 filing for Mineralys Therapeutics Inc. dated July 10, indicating an insider transaction for the company. The brief mention includes the stock symbol MLYS, which saw a -2.00% change.", "url": "https://za.investing.com/news/stock-market-news/form-4-mineralys-therapeutics-inc-for-10-july-93CH-4365136", "source_name": "Investing.com South Africa", "published_at": "2026-07-10T23:40:31", "published_display": "10 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys (MLYS) reports 2,171-share exercise; Rodman sales listed", "summary": "Mineralys Therapeutics, Inc. (MLYS) filed a Form 144 disclosing a broker-assisted cashless exercise of 2,171 shares on July 9, 2026. The filing also details multiple sales by David Rodman between April 9, 2026, and June 17, 2026, with individual transactions ranging from 416 to 1", "url": "https://www.stocktitan.net/sec-filings/MLYS/144-mineralys-therapeutics-inc-sec-filing-11a64cb17adb.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:11:32", "published_display": "09 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Index Removal, ENDO 2026 Data and a $150M Raise Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative?", "summary": "Mineralys Therapeutics (MLYS) recently experienced removal from Russell indices but simultaneously announced new ENDO 2026 data, a $150 million public offering, and expanded global rights to its lead drug, lorundrostat. These developments, coupled with a $500 million loan facilit", "url": "https://www.sahmcapital.com/news/content/did-index-removal-endo-2026-data-and-a-150m-raise-just-shift-mineralys-therapeutics-mlys-investment-narrative-2026-07-06", "source_name": "Sahm", "published_at": "2026-07-07T06:40:18", "published_display": "07 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Mineralys Therapeutics Insiders Been Selling Stock?", "summary": "This article analyzes recent insider selling activity at Mineralys Therapeutics. It investigates whether insiders have been selling stock and what the implications might be for investors. The article aims to inform readers about the extent and trends of these insider transactions", "url": "https://www.moomoo.com/news/post/72459505/have-mineralys-therapeutics-insiders-been-selling-stock", "source_name": "Moomoo", "published_at": "2026-07-03T18:12:04", "published_display": "03 Jul 2026 18:12", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/500-million-funding-deal-could-134113992.html", "source_name": "Insider Monkey", "published_at": "2026-07-03T13:41:13+00:00", "published_display": "03 Jul 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Insiders Sold Mineralys Therapeutics Shares Recently?", "summary": "Mineralys Therapeutics President Jon Congleton recently sold US$2.0m worth of shares, decreasing his holding by 14%. This sale, along with a larger one earlier in the year, indicates a trend of insider selling. Despite existing insider ownership, the lack of recent insider buying", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/have-insiders-sold-mineralys-therapeutics-shares-recently", "source_name": "Simply Wall Street", "published_at": "2026-07-03T12:12:13", "published_display": "03 Jul 2026 12:12", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat\u2019s Expanding Cardiovascular Potential?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/mineralys-therapeutics-inc-mlys-stock-195814924.html", "source_name": "Insider Monkey", "published_at": "2026-07-02T19:58:14+00:00", "published_display": "02 Jul 2026 19:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics Insider Sold Shares Worth $2,696,322, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mineralys-therapeutics-insider-sold-shares-081054086.html", "source_name": "MT Newswires", "published_at": "2026-07-01T08:10:54+00:00", "published_display": "01 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics Insider Sold Shares Worth $1,960,601, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mineralys-therapeutics-insider-sold-shares-081032321.html", "source_name": "MT Newswires", "published_at": "2026-07-01T08:10:32+00:00", "published_display": "01 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) CEO sells 75K shares under Rule 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQN1RzSkVhdTU2S1pHMlVVd0NzQW1qX0w3SDBVUlJyZnRSVFcxOVprMHhHUU1nSDdtLXVESnRLdVNlV0ZqRzhiVWlBOWtJWGd3cFdtN3JycHVIZHU3TE01RFMweTZ3dC1XMDFPZWJzZmo4VUQtZS1FTldZeGN1X05lRzN1emdab01SZTJnUEJqejMtRjJKaU1SR3BZMmFhNDE0NFRsTHB2dG9TYjhrY3JsOHpZUmtoOXhQNVpjRA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) Form 144 lists 90,730 shares sold and RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQMDA0TURSbmYwLWhTbkFHb3Q0S1h3emRSVktyWG50Z1QzbVh5eHlFLTNHci11YWRpaXdSemh4dm9kYkFiQ3FaSWNOWTNNQXN6VTl3QmpuSktYZ3dJNElIV3ZsdTBpUXFybWtTSk9ZOUxJVm1fRjR0U0RkbTZuV2p6YlJrSTVCWGZPaEhlWTNQMkg0bXBQZHEtRzVVOGtWVjloQjEyZ053?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (NASDAQ: MLYS) flagged sale of 104,124 shares via cashless exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOZmloT3gxRmpoNE5UQWJEUXJqZU4xYkpDRmIyU0k2RkVUNURKUnBfbEtrUjFQVHpUYjlzYWdRZzlYbTNOYllMQVM0d0dUZUpvYkZETkFTd0pTVkhKVjk5NjBJMGxOZmMxVzVzVGs0U3ZSZ2gwMEU1UzlVSFFXUjloTFoxTWN0RWpucmpBT25XMkdlaHlzN0tldUhYaWdlT3l0MEpIblVB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision", "summary": "", "url": "https://finance.yahoo.com/m/a8914fe3-c642-30c0-ac9c-166dfd19baf5/what-a-%24350%2C000-insider-sale.html", "source_name": "Motley Fool", "published_at": "2026-06-23T21:39:01+00:00", "published_display": "23 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxORnlBUFNXZWFsN3lieDVuM1Jxck5kYkoxeFlSTV9oMGY5VkszVU5NRERCVUVqdGJkQlVqNkxYczM3dGVDZW9uYk16VzVzUURSWGNyOWt3MGl5UWRzZTVna3p5T2lRdDlWVmNvZ0dNMFEtLUNDNUtLOGZTRS1SMVI3NHhXTk9DSFJqeHQ2RnlwMExoU1gzdml2YjRzVC1GdjRPZGp4Q2IxQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mineralys-therapeutics-presents-breaking-data-140000450.html", "source_name": "GlobeNewswire", "published_at": "2026-06-14T14:00:00+00:00", "published_display": "14 Jun 2026 14:00", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for Lorundrostat", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mineralys-therapeutics-mlys-repurchase-potential-102032829.html", "source_name": "Insider Monkey", "published_at": "2026-06-11T10:20:32+00:00", "published_display": "11 Jun 2026 10:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics Stock Plummets 25% With 6-Day Losing Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPb1JISkVvVUg1TWNtVlhWYnlDVm4ySER4NDd0ejc5SkQ1bUkwOVl0YXlvU1BwTnFlTXdXazVaZzRvdVc0NHBtRVVZbTk5Q1M0ODB1c290eDNFYUd6eUZjVFdHLXNGVU1xWXFjYi1Sc3lfd3JoeHlsZnlOcWhjVjhjS211bGJIYTdNOEZUSUg3MWl0MXFfZ01ZM2lfVEJ1ak41YmJyVUFFUzIwWld0VlN6RWFaMVIxSHBqc3hiT0JJNEYtSEtPWExtUlVLOTlMYU15?oc=5", "source_name": "Trefis", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOUkxkX0FlS2swMmduNnJwMFpJSE9PZnlqWEJnNlRTd1BlZ1YxTjVZVmtpM0xVSHUzYklIaWhveXV1S2JUMkNMQTBrZ1hjWC03MlNzRWtTOXROXzNrWFNyanZBOHB4bnkwSDNQejNWbnRlcDBLYTdkUXB3dnlLRUhURmdnMWhEZEU0N3ZmZTZjc2xITjNQY0N3ZEpWQTV5bi1PbEp0MWZZbjZPdEMzbkdGQmZnWkFLQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Mineralys raises $150M to help fund $200M royalty deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOYVRJZ3JaR241Mm9lOVVBZGRpeUV6R0w2alpCYTNUQ1lsZUFMOFA3b2psRUJQdFltNTdGZHdaVFdmQlFDZy1CcUJmNnd6SVZTNWJZa3lMTktfNGdjemdzZVVvSWsxVHo2a0Nhb1pyc3MyWVRkbGdkTC0xQ3B4N3htRW5sWUpzTnJCRURBeXcxNDJHQW96b0ZieG93eVlrRGw5b2RCRmVhcEx0Tkp6WE5HM2ZRMFFTSkgyQVQtNER4QTU?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$MLYS stock is down 13% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNclUxbTFyYzRlQzdjc2duM1ZsYjBTclZwd2IwNUluUHZITDFzX0w4Z3VHNDlWN3Jnb2pzYm4wWmRHZG5BNXdRX3NoSkJ2U2JZRmtJSTVfTjJjMFdZSHlrNXJRY2pQOHVsRnlSX2VLYWV0dkx1aF9GR05zWk1Iajh6NW5MN2hvWVdtR042QmxDUGppc2l2bkNwQ1ZmOVBQUFF6QXZn?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mineralys fireside chat at Bank of America conference streams May 12", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxORm1UWFlBQVh2QjlNUTlpQURQU1hwU3ZSanNWNEF6LU9PcFlLTmVUTU1ncGdkWGJOY21wY2NzNU5iNUtQb3JBMWpTa2dvMnVqZHBHS2FEeGFvbUVVWERZNTRDRTB2eTdjSnYwZzVuM0U4WmczSFRlVGdkaFN0VUc4RzR5clZQS3ZBdFU0eEhkNVNtb004dzlFT2x1NHJ5QnNON3NNYVoyU2ZVNHlmVGwyZUNYSG43QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mineralys Therapeutics, Inc. (MLYS) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOQkRHaktROFlldFFMQ2ttMFhqVmFUMTh0dlVxdFgxMnpRMXhxeC1JdUdLUEdJeHpmZ1ZrdWlQU0t6aVBLclVuVVA5bjRCOFlGdGw1U1ZjUDgwX1ZhUzhZbVJ3dVZQMTZKQ3hGZTBtVEswcVQ4QWpGQVU2Yi1lbFRWbWtjd1lqdzdvZk1VQzB0SlBabDZTUl9PbUVTSkt5WWluMHV3?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mineralys (MLYS) CMO logs small 10b5-1 share sale and option exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNeUU0aEpZWWNZX0JqclFCdFozLWMwc3FpVS1DUzlOZGdrOEl0dDRoZ01JMlpCYVo4ejZCbDVLZ1V2VkF4S1Z2TzR0VEVING5NNWxEbWJWblFkSDJaYzBtZ0JvWTI1blFMOU1ZQ01odElqS1pMaXVCOVBGT0hRVXdwcWRsXzdGN1lfWVpDSEx2Y3BXZlBxN3RUUUs0eFh4N2NJMmJNMHBqcW8wMVJZWlY1WjI2eVhfWXhqQTR3Ug?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Mineralys Therapeutics (MLYS) affiliate plans 7,438-share stock sale after options exercise", "summary": "An affiliate of Mineralys Therapeutics (MLYS) has filed a Form 144 notice for the potential sale of 7,438 shares of common stock. This sale, valued at $199,884.80, is scheduled for July 21, 2026, following the exercise of employee stock options via a broker-assisted cashless exer", "url": "https://www.stocktitan.net/sec-filings/MLYS/144-mineralys-therapeutics-inc-sec-filing-5744e9a702e7.html", "source_name": "Stock Titan", "published_at": "2026-07-21T20:40:14", "published_display": "21 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares By Investing.com", "summary": "Mineralys Therapeutics CMO David Rodman sold 416 shares for $11,036 while simultaneously acquiring the same number of shares by exercising stock options for $6,423 under a pre-arranged trading plan. Post-transaction, Rodman holds 51,384 shares and 3,334 stock options. The company", "url": "https://za.investing.com/news/stock-market-news/mineralys-therapeutics-cmo-david-rodman-disposes-of-11036-in-shares-93CH-4377548", "source_name": "Investing.com South Africa", "published_at": "2026-07-21T15:40:14", "published_display": "21 Jul 2026 15:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Mineralys Therapeutics Inc For: 21 July", "summary": "This article states that a Form 4 was filed for Mineralys Therapeutics Inc. on July 21st, implying a report of changes in beneficial ownership of the company's securities. The content is primarily a placeholder for this regulatory filing, with minimal actual news text and surroun", "url": "https://ca.investing.com/news/stock-market-news/form-4-mineralys-therapeutics-inc-for-21-july-93CH-4743146", "source_name": "Investing.com Canada", "published_at": "2026-07-21T09:40:18", "published_display": "21 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares", "summary": "Mineralys Therapeutics' Chief Medical Officer, David Rodman, recently sold 416 shares for $11,036 and simultaneously acquired 416 shares through stock option exercise for $6,423. These transactions were under a Rule 10b5-1 trading plan. The company's stock has seen a 96% return o", "url": "https://www.investing.com/news/insider-trading-news/mineralys-therapeutics-cmo-david-rodman-disposes-of-11036-in-shares-93CH-4802288", "source_name": "Investing.com", "published_at": "2026-07-21T09:40:18", "published_display": "21 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Mineralys Therapeutics For: 17 July By Investing.com", "summary": "This article from Investing.com is a brief notice about a Form 144 filing for Mineralys Therapeutics (MLYS) on July 17. Form 144 is an SEC filing that indicates an intent to sell restricted securities. The article provides minimal detail beyond this announcement.", "url": "https://ca.investing.com/news/stock-market-news/form-144-mineralys-therapeutics-for-17-july-93CH-4740463", "source_name": "Investing.com Canada", "published_at": "2026-07-17T21:11:19", "published_display": "17 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) insider schedules 416-share sale after option exercise", "summary": "Mineralys Therapeutics (MLYS) insider David Rodman has scheduled a sale of 416 common shares on July 17, 2026, following the exercise of employee stock options via a cashless exercise through Merrill Lynch. This notice also details several prior share sales by Rodman between Apri", "url": "https://www.stocktitan.net/sec-filings/MLYS/144-mineralys-therapeutics-inc-sec-filing-2c5d30ba343d.html", "source_name": "Stock Titan", "published_at": "2026-07-17T20:09:46", "published_display": "17 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date", "summary": "", "url": "https://finance.yahoo.com/m/f28c48e6-c98a-3312-a19f-022e3dbbc272/a-mineralys-insider-banked-a.html", "source_name": "Motley Fool", "published_at": "2026-07-16T21:05:05+00:00", "published_display": "16 Jul 2026 21:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What to Know About This Mineralys Insider Sale Before a December FDA Date", "summary": "", "url": "https://finance.yahoo.com/m/e0203402-60fc-310d-8601-a25fe170a689/what-to-know-about-this.html", "source_name": "Motley Fool", "published_at": "2026-07-16T20:57:38+00:00", "published_display": "16 Jul 2026 20:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary", "summary": "Mineralys Therapeutics (MLYS) provided updates at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026. Key announcements included the late 2025 NDA submission for lorundrostat with a PDUFA date of December 6, 2026, and preparations for its launch. The company also ", "url": "https://quartr.com/events/mineralys-therapeutics-inc-mlys-goldman-sachs-47th-annual-global-healthcare-conference-2026_FkT72ETU", "source_name": "Quartr", "published_at": "2026-07-16T21:09:46", "published_display": "16 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) Q3 2025 earnings summary", "summary": "Mineralys Therapeutics (MLYS) reported its Q3 2025 earnings, highlighting plans for NDA submission of lorundrostat by early 2026 following positive FDA feedback. The company's cash position of $593.6 million is expected to fund operations into 2028, with significant public equity", "url": "https://quartr.com/events/mineralys-therapeutics-inc-mlys-q3-2025_FkT7DPvK", "source_name": "Quartr", "published_at": "2026-07-16T10:40:56", "published_display": "16 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Mineralys Therapeutics Inc For: 15 July By Investing.com", "summary": "This article reports on a Form 4 filing for Mineralys Therapeutics Inc. for July 15. The brief piece includes the company's stock symbol (MLYS) and a minor percentage change. The content primarily lists market data for various indices, commodities, bonds, and shares.", "url": "https://ng.investing.com/news/stock-market-news/form-4-mineralys-therapeutics-inc-for-15-july-93CH-2601912", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T02:39:36", "published_display": "16 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: CEO Jon Congleton Sells 10,700 Shares of Mineralys Therapeutics Inc (MLYS)", "summary": "Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton sold 10,700 shares on July 13, 2026, reducing his total holdings to 603,621 shares. This transaction is part of a trend of more insider selling than buying at the company over the past year. Shares were trading at $27.24 at the ", "url": "https://www.gurufocus.com/news/8961504/insider-sell-ceo-jon-congleton-sells-10700-shares-of-mineralys-therapeutics-inc-mlys", "source_name": "GuruFocus", "published_at": "2026-07-16T02:39:36", "published_display": "16 Jul 2026 02:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics CEO Jon Congleton sells $291,441 in stock", "summary": "Mineralys Therapeutics CEO Jon Congleton sold 10,700 shares of company stock, valued at $291,441, on July 13, 2026, as part of a pre-planned trading arrangement. Following this sale, Congleton still owns 603,621 shares. The company's stock has seen a significant return over the p", "url": "https://www.investing.com/news/insider-trading-news/mineralys-therapeutics-ceo-jon-congleton-sells-291441-in-stock-93CH-4794575", "source_name": "Investing.com", "published_at": "2026-07-16T01:39:36", "published_display": "16 Jul 2026 01:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys therapeutics CMO Rodman sells $556,671 in shares", "summary": "Mineralys Therapeutics' Chief Medical Officer, Rodman David Malcom, sold company shares totaling $556,671 across two transactions in July 2026, executed under a pre-arranged trading plan. Concurrently, he acquired shares worth $102,365 through stock option exercises. The company ", "url": "https://www.investing.com/news/insider-trading-news/mineralys-therapeutics-cmo-rodman-sells-556671-in-shares-93CH-4794576", "source_name": "Investing.com", "published_at": "2026-07-16T01:39:36", "published_display": "16 Jul 2026 01:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) CMO sells 20,407 shares and exercises options", "summary": "Mineralys Therapeutics (MLYS) Chief Medical Officer David Malcom Rodman sold 20,407 common shares and exercised options for 14,058 common shares on July 13 and 15, 2026. These transactions were executed under a Rule 10b5-1 trading plan adopted on October 6, 2025. Following these ", "url": "https://www.stocktitan.net/sec-filings/MLYS/form-4-mineralys-therapeutics-inc-insider-trading-activity-e2acc69c7499.html", "source_name": "Stock Titan", "published_at": "2026-07-16T00:40:56", "published_display": "16 Jul 2026 00:40", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) CEO logs 10,700-share sale under Rule 10b5-1 plan", "summary": "Mineralys Therapeutics CEO Jon Congleton sold 10,700 shares of common stock on July 13, 2026, at a weighted-average price of $27.2375 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in January 2025. Following the sale, Congleton dir", "url": "https://www.stocktitan.net/sec-filings/MLYS/form-4-mineralys-therapeutics-inc-insider-trading-activity-b51ef8b1e8b0.html", "source_name": "Stock Titan", "published_at": "2026-07-16T00:39:36", "published_display": "16 Jul 2026 00:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Planned 6,349-share stock sale by Mineralys Therapeutics (NASDAQ: MLYS)", "summary": "An insider at Mineralys Therapeutics (NASDAQ: MLYS), David Rodman, plans to sell 6,349 shares of common stock through Merrill Lynch on July 15, 2026, with an aggregate market value of approximately $168,954.55. These shares were acquired via an exercise of employee stock options ", "url": "https://www.stocktitan.net/sec-filings/MLYS/144-mineralys-therapeutics-inc-sec-filing-979899871b67.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:39:36", "published_display": "15 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Planned 14,058-share sale at Mineralys Therapeutics (NASDAQ: MLYS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQUG9lcm16bkFtRHUxUm95WFZ0UE1ONWZwRFFTTllLTWdZMmRjM1FOQ3AzZXVuU0tKX1NkVE5zckxEeDJ5N09UTm1LQUFBWkhRbHJKQmwwODdnWU0zZXdRNmJPeS1FcDgycTE1endYdTA1X0Q2T0tHUjN0dnhxWnlYMkdPekkyNm1hcTV1Q0hQVkJEcUx2YmFGRGxYSE1lLUJFVVRVZ0VNM1o?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T15:08:29+00:00", "published_display": "14 Jul 2026 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Mineralys Therapeutics For: 13 July By Investing.com", "summary": "The article announces the filing of Form 144 for Mineralys Therapeutics on July 13. It is a brief report from Investing.com, likely indicating an insider transaction or a notice of proposed sale of securities. The article provides minimal detail beyond the date and company name, ", "url": "https://ng.investing.com/news/stock-market-news/form-144-mineralys-therapeutics-for-13-july-93CH-2597728", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T02:10:38", "published_display": "14 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) insider plans 10,700-share Rule 144 stock sale", "summary": "Mineralys Therapeutics (MLYS) insider Jon Congleton plans to sell 10,700 shares of common stock under Rule 144, valued at $291,441.17. The sale, set for July 13, 2026, via Merrill Lynch on Nasdaq, follows the vesting of restricted stock units. Congleton has made previous sales to", "url": "https://www.stocktitan.net/sec-filings/MLYS/144-mineralys-therapeutics-inc-sec-filing-3f94c8183c17.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:10:39", "published_display": "13 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) insider details stock option exercise and sales", "summary": "An affiliate of Mineralys Therapeutics, Inc. (MLYS) has a planned sale of common stock via Merrill Lynch on NASDAQ, stemming from an employee stock option exercise on July 13, 2026. Insider David Rodman has made multiple open-market sales of the company's common stock in the past", "url": "https://www.stocktitan.net/sec-filings/MLYS/144-mineralys-therapeutics-inc-sec-filing-fc3ec0482ec2.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:10:38", "published_display": "13 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Mineralys Therapeutics, Inc. \u2013 NASDAQ:MLYS", "summary": "This article provides details about Mineralys Therapeutics, Inc. (NASDAQ: MLYS), including its stock information, market status, and links to financial data, news, and community discussions on TradingView. It also lists the various data providers for the information presented.", "url": "https://www.tradingview.com/symbols/NASDAQ-MLYS/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-13T08:39:36", "published_display": "13 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics CMO Rodman sells $65,781 in stock", "summary": "Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, sold 2,171 shares of the company's stock for $65,781 on July 9, 2026, under a Rule 10b5-1 trading plan. This sale occurred after the stock delivered a 94% return over the past year, though shares are currently tr", "url": "https://www.investing.com/news/insider-trading-news/mineralys-therapeutics-cmo-rodman-sells-65781-in-stock-93CH-4787156", "source_name": "Investing.com", "published_at": "2026-07-11T07:10:46", "published_display": "11 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) CMO sells 2,171 shares after option exercise", "summary": "Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, exercised 2,171 stock options at $16.00 per share and subsequently sold the same number of common shares at $30.30 per share. This transaction was pre-planned under a Rule 10b5-1 trading plan adopted in October 2", "url": "https://www.stocktitan.net/sec-filings/MLYS/form-4-mineralys-therapeutics-inc-insider-trading-activity-81cf9763ea99.html", "source_name": "Stock Titan", "published_at": "2026-07-11T00:40:31", "published_display": "11 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Mineralys Therapeutics Inc For: 10 July By Investing.com", "summary": "This article reports on a Form 4 filing for Mineralys Therapeutics Inc. dated July 10, indicating an insider transaction for the company. The brief mention includes the stock symbol MLYS, which saw a -2.00% change.", "url": "https://za.investing.com/news/stock-market-news/form-4-mineralys-therapeutics-inc-for-10-july-93CH-4365136", "source_name": "Investing.com South Africa", "published_at": "2026-07-10T23:40:31", "published_display": "10 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys (MLYS) reports 2,171-share exercise; Rodman sales listed", "summary": "Mineralys Therapeutics, Inc. (MLYS) filed a Form 144 disclosing a broker-assisted cashless exercise of 2,171 shares on July 9, 2026. The filing also details multiple sales by David Rodman between April 9, 2026, and June 17, 2026, with individual transactions ranging from 416 to 1", "url": "https://www.stocktitan.net/sec-filings/MLYS/144-mineralys-therapeutics-inc-sec-filing-11a64cb17adb.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:11:32", "published_display": "09 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Index Removal, ENDO 2026 Data and a $150M Raise Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative?", "summary": "Mineralys Therapeutics (MLYS) recently experienced removal from Russell indices but simultaneously announced new ENDO 2026 data, a $150 million public offering, and expanded global rights to its lead drug, lorundrostat. These developments, coupled with a $500 million loan facilit", "url": "https://www.sahmcapital.com/news/content/did-index-removal-endo-2026-data-and-a-150m-raise-just-shift-mineralys-therapeutics-mlys-investment-narrative-2026-07-06", "source_name": "Sahm", "published_at": "2026-07-07T06:40:18", "published_display": "07 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Mineralys Therapeutics Insiders Been Selling Stock?", "summary": "This article analyzes recent insider selling activity at Mineralys Therapeutics. It investigates whether insiders have been selling stock and what the implications might be for investors. The article aims to inform readers about the extent and trends of these insider transactions", "url": "https://www.moomoo.com/news/post/72459505/have-mineralys-therapeutics-insiders-been-selling-stock", "source_name": "Moomoo", "published_at": "2026-07-03T18:12:04", "published_display": "03 Jul 2026 18:12", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/500-million-funding-deal-could-134113992.html", "source_name": "Insider Monkey", "published_at": "2026-07-03T13:41:13+00:00", "published_display": "03 Jul 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Insiders Sold Mineralys Therapeutics Shares Recently?", "summary": "Mineralys Therapeutics President Jon Congleton recently sold US$2.0m worth of shares, decreasing his holding by 14%. This sale, along with a larger one earlier in the year, indicates a trend of insider selling. Despite existing insider ownership, the lack of recent insider buying", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/have-insiders-sold-mineralys-therapeutics-shares-recently", "source_name": "Simply Wall Street", "published_at": "2026-07-03T12:12:13", "published_display": "03 Jul 2026 12:12", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat\u2019s Expanding Cardiovascular Potential?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/mineralys-therapeutics-inc-mlys-stock-195814924.html", "source_name": "Insider Monkey", "published_at": "2026-07-02T19:58:14+00:00", "published_display": "02 Jul 2026 19:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics Insider Sold Shares Worth $2,696,322, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mineralys-therapeutics-insider-sold-shares-081054086.html", "source_name": "MT Newswires", "published_at": "2026-07-01T08:10:54+00:00", "published_display": "01 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics Insider Sold Shares Worth $1,960,601, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mineralys-therapeutics-insider-sold-shares-081032321.html", "source_name": "MT Newswires", "published_at": "2026-07-01T08:10:32+00:00", "published_display": "01 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) CEO sells 75K shares under Rule 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQN1RzSkVhdTU2S1pHMlVVd0NzQW1qX0w3SDBVUlJyZnRSVFcxOVprMHhHUU1nSDdtLXVESnRLdVNlV0ZqRzhiVWlBOWtJWGd3cFdtN3JycHVIZHU3TE01RFMweTZ3dC1XMDFPZWJzZmo4VUQtZS1FTldZeGN1X05lRzN1emdab01SZTJnUEJqejMtRjJKaU1SR3BZMmFhNDE0NFRsTHB2dG9TYjhrY3JsOHpZUmtoOXhQNVpjRA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) Form 144 lists 90,730 shares sold and RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQMDA0TURSbmYwLWhTbkFHb3Q0S1h3emRSVktyWG50Z1QzbVh5eHlFLTNHci11YWRpaXdSemh4dm9kYkFiQ3FaSWNOWTNNQXN6VTl3QmpuSktYZ3dJNElIV3ZsdTBpUXFybWtTSk9ZOUxJVm1fRjR0U0RkbTZuV2p6YlJrSTVCWGZPaEhlWTNQMkg0bXBQZHEtRzVVOGtWVjloQjEyZ053?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (NASDAQ: MLYS) flagged sale of 104,124 shares via cashless exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOZmloT3gxRmpoNE5UQWJEUXJqZU4xYkpDRmIyU0k2RkVUNURKUnBfbEtrUjFQVHpUYjlzYWdRZzlYbTNOYllMQVM0d0dUZUpvYkZETkFTd0pTVkhKVjk5NjBJMGxOZmMxVzVzVGs0U3ZSZ2gwMEU1UzlVSFFXUjloTFoxTWN0RWpucmpBT25XMkdlaHlzN0tldUhYaWdlT3l0MEpIblVB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision", "summary": "", "url": "https://finance.yahoo.com/m/a8914fe3-c642-30c0-ac9c-166dfd19baf5/what-a-%24350%2C000-insider-sale.html", "source_name": "Motley Fool", "published_at": "2026-06-23T21:39:01+00:00", "published_display": "23 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxORnlBUFNXZWFsN3lieDVuM1Jxck5kYkoxeFlSTV9oMGY5VkszVU5NRERCVUVqdGJkQlVqNkxYczM3dGVDZW9uYk16VzVzUURSWGNyOWt3MGl5UWRzZTVna3p5T2lRdDlWVmNvZ0dNMFEtLUNDNUtLOGZTRS1SMVI3NHhXTk9DSFJqeHQ2RnlwMExoU1gzdml2YjRzVC1GdjRPZGp4Q2IxQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mineralys-therapeutics-presents-breaking-data-140000450.html", "source_name": "GlobeNewswire", "published_at": "2026-06-14T14:00:00+00:00", "published_display": "14 Jun 2026 14:00", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for Lorundrostat", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mineralys-therapeutics-mlys-repurchase-potential-102032829.html", "source_name": "Insider Monkey", "published_at": "2026-06-11T10:20:32+00:00", "published_display": "11 Jun 2026 10:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics Stock Plummets 25% With 6-Day Losing Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPb1JISkVvVUg1TWNtVlhWYnlDVm4ySER4NDd0ejc5SkQ1bUkwOVl0YXlvU1BwTnFlTXdXazVaZzRvdVc0NHBtRVVZbTk5Q1M0ODB1c290eDNFYUd6eUZjVFdHLXNGVU1xWXFjYi1Sc3lfd3JoeHlsZnlOcWhjVjhjS211bGJIYTdNOEZUSUg3MWl0MXFfZ01ZM2lfVEJ1ak41YmJyVUFFUzIwWld0VlN6RWFaMVIxSHBqc3hiT0JJNEYtSEtPWExtUlVLOTlMYU15?oc=5", "source_name": "Trefis", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOUkxkX0FlS2swMmduNnJwMFpJSE9PZnlqWEJnNlRTd1BlZ1YxTjVZVmtpM0xVSHUzYklIaWhveXV1S2JUMkNMQTBrZ1hjWC03MlNzRWtTOXROXzNrWFNyanZBOHB4bnkwSDNQejNWbnRlcDBLYTdkUXB3dnlLRUhURmdnMWhEZEU0N3ZmZTZjc2xITjNQY0N3ZEpWQTV5bi1PbEp0MWZZbjZPdEMzbkdGQmZnWkFLQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Mineralys raises $150M to help fund $200M royalty deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOYVRJZ3JaR241Mm9lOVVBZGRpeUV6R0w2alpCYTNUQ1lsZUFMOFA3b2psRUJQdFltNTdGZHdaVFdmQlFDZy1CcUJmNnd6SVZTNWJZa3lMTktfNGdjemdzZVVvSWsxVHo2a0Nhb1pyc3MyWVRkbGdkTC0xQ3B4N3htRW5sWUpzTnJCRURBeXcxNDJHQW96b0ZieG93eVlrRGw5b2RCRmVhcEx0Tkp6WE5HM2ZRMFFTSkgyQVQtNER4QTU?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$MLYS stock is down 13% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNclUxbTFyYzRlQzdjc2duM1ZsYjBTclZwd2IwNUluUHZITDFzX0w4Z3VHNDlWN3Jnb2pzYm4wWmRHZG5BNXdRX3NoSkJ2U2JZRmtJSTVfTjJjMFdZSHlrNXJRY2pQOHVsRnlSX2VLYWV0dkx1aF9GR05zWk1Iajh6NW5MN2hvWVdtR042QmxDUGppc2l2bkNwQ1ZmOVBQUFF6QXZn?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys fireside chat at Bank of America conference streams May 12", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxORm1UWFlBQVh2QjlNUTlpQURQU1hwU3ZSanNWNEF6LU9PcFlLTmVUTU1ncGdkWGJOY21wY2NzNU5iNUtQb3JBMWpTa2dvMnVqZHBHS2FEeGFvbUVVWERZNTRDRTB2eTdjSnYwZzVuM0U4WmczSFRlVGdkaFN0VUc4RzR5clZQS3ZBdFU0eEhkNVNtb004dzlFT2x1NHJ5QnNON3NNYVoyU2ZVNHlmVGwyZUNYSG43QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mineralys Therapeutics, Inc. (MLYS) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOQkRHaktROFlldFFMQ2ttMFhqVmFUMTh0dlVxdFgxMnpRMXhxeC1JdUdLUEdJeHpmZ1ZrdWlQU0t6aVBLclVuVVA5bjRCOFlGdGw1U1ZjUDgwX1ZhUzhZbVJ3dVZQMTZKQ3hGZTBtVEswcVQ4QWpGQVU2Yi1lbFRWbWtjd1lqdzdvZk1VQzB0SlBabDZTUl9PbUVTSkt5WWluMHV3?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mineralys (MLYS) CMO logs small 10b5-1 share sale and option exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNeUU0aEpZWWNZX0JqclFCdFozLWMwc3FpVS1DUzlOZGdrOEl0dDRoZ01JMlpCYVo4ejZCbDVLZ1V2VkF4S1Z2TzR0VEVING5NNWxEbWJWblFkSDJaYzBtZ0JvWTI1blFMOU1ZQ01odElqS1pMaXVCOVBGT0hRVXdwcWRsXzdGN1lfWVpDSEx2Y3BXZlBxN3RUUUs0eFh4N2NJMmJNMHBqcW8wMVJZWlY1WjI2eVhfWXhqQTR3Ug?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 68, "sentiment_summary": {"positive": 11, "negative": 11, "neutral": 46, "score": 50, "total": 68, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 86, "events": [{"event": "general", "label": "Market update", "weight": 27.3, "count": 49}, {"event": "earnings", "label": "Earnings", "weight": 7.5, "count": 15}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 11}, "market_context": {"has_market_context": true, "latest_close": 27.09, "latest_week": "2026-07-17", "one_week_move": -4.5, "four_week_move": 10.0, "twelve_week_move": -1.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.194338, "market_dynamics_buy_signal": false, "relative_strength": -19.812772, "fair_value_gap": 49.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 57.9694, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.5% over one week, +10.0% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 16}, {"label": "Market source", "count": 10}, {"label": "Investing.com", "count": 4}, {"label": "Motley Fool", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "Insider Monkey", "count": 3}, {"label": "Investing.com South Africa", "count": 2}, {"label": "Investing.com Canada", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 60}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 49}, {"label": "Earnings", "count": 15}, {"label": "Deals and strategy", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "86/100 classification confidence."}, {"label": "Company focus", "value": "60", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.5% over one week, +10.0% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Mineralys Therapeutics (MLYS) affiliate plans 7,438-share stock sale after options exercise"}], "updated_at": "2026-07-22T12:47:29.545381+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}